证券代码：600227 证券简称：赤天化 编号：2025-051 贵州赤天化股份有限公司关于提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●被担保人名称及是否为上市公司关联人：被担保人贵州大秦肿瘤医院有限公司（以下简称"大秦医 院"）和贵州赤天化桐梓化工有限公司（以下简称"桐梓化工"）系公司的全资子公司。 ●本次担保金额及已实际为其提供的担保余额：①2025年7月，公司对大秦医院增加担保金额为2,446万 元，截止至2025年7月31日，公司累计为大秦医院提供担保余额为63,294.44万元；②2025年7月，公司对 桐梓化工增加担保金额为7,000万元，截止至2025年7月31日，公司累计为桐梓化工提供担保余额为 52,080万元；2025年7月，公司提供担保的子公司归还借款金额11,100万元，截止至2025年7月31日，公 司及公司控股子公司对外担保总额为115,374.44万元，对外担保均为公司为报表合并范围内的子公司提 供的担保。 ●本次担保是否有反担保：否 ●对外担保逾期的累计 ...

证券代码：600227 证券简称：赤天化 编号：2025-051 贵州赤天化股份有限公司 关于提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●被担保人名称及是否为上市公司关联人：被担保人贵州大秦肿 瘤医院有限公司（以下简称"大秦医院"）和贵州赤天化桐梓化工有 限公司（以下简称"桐梓化工"）系公司的全资子公司。 ●本次担保金额及已实际为其提供的担保余额：①2025年7月， 公司对大秦医院增加担保金额为2,446万元，截止至2025年7月31日， 公司累计为大秦医院提供担保余额为63,294.44万元；②2025年7月， 公司对桐梓化工增加担保金额为7,000万元，截止至2025年7月31日， 公司累计为桐梓化工提供担保余额为52,080万元；2025年7月，公司 提供担保的子公司归还借款金额11,100万元，截止至2025年7月31日， 公司及公司控股子公司对外担保总额为115,374.44万元，对外担保均 为公司为报表合并范围内的子公司提供的担保。 ●本次担保是否有反担保：否 ●对外担保逾 ...

关于全资子公司安佳矿业停产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、基本情况 贵州赤天化股份有限公司（以下简称"公司"）全资子公司贵州 安佳矿业有限公司（以下简称"安佳矿业"）于 2025 年 7 月 15 日凌 晨 2 时 30 分左右发生一起事故，致一人受伤，后经抢救无效死亡。 初步查明是由于安佳矿业煤仓发生溃水，水流从主斜井上部向下冲刷， 将 1 名主井作业人员冲倒并随水流滚落至井底。具体原因有待进一步 调查。按照有关规定，矿井在此期间停止除通风、排水、瓦斯检查外 的一切作业活动。 证券代码:600227 证券简称:赤 天 化 编号:2025-050 贵州赤天化股份有限公司 安佳矿业主要从事煤炭开采、销售，负责运营贵州安佳矿业有限 公司桐梓县花秋镇花秋二矿（以下简称"花秋二矿"），花秋二矿核 定产能 60 万吨/年。安佳矿业 2024 年末总资产 99,505.86 万元，占 公司经审计合并报表总资产的 20.58%，2024 年度合并抵消前实现营 业收入 2,446.93 万元，占公司经审计合并报表营 ...

[Current Period Performance Forecast](index=1&type=section&id=一%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E6%83%85%E5%86%B5) The company anticipates continued losses in H1 2025, with net profit attributable to shareholders estimated between **RMB -35 million and -52 million**, and non-recurring net profit between **RMB -36 million and -53 million** 2025 Semi-Annual Performance Forecast | Performance Indicator (2025 Semi-Annual Forecast) | Amount Range (RMB) | | :------------------------------------------------ | :------------------------------- | | Net Profit Attributable to Parent Company Shareholders | -35 Million RMB to -52 Million RMB | | Net Profit Attributable to Parent Company Shareholders After Deducting Non-Recurring Gains and Losses | -36 Million RMB to -53 Million RMB | - The company explicitly states that the performance forecast data for this period has not been audited by a certified public accountant[3](index=3&type=chunk) [Operating Performance and Financial Status for the Same Period Last Year](index=1&type=section&id=二%E3%80%81%E4%B8%8A%E5%B9%B4%E5%90%8C%E6%9C%9F%E7%BB%8F%E8%90%A5%E4%B8%9A%E7%BB%A9%E5%92%8C%E8%B4%A2%E5%8A%A1%E7%8A%B6%E5%86%B5) In H1 2024, the company reported a net loss attributable to parent company shareholders of **RMB 36.743 million** and a non-recurring net loss of **RMB 50.1754 million**, with earnings per share at **RMB -0.0217** 2024 Semi-Annual Operating Performance | Performance Indicator (2024 Semi-Annual) | Amount/Value (RMB) | | :--------------------------------------- | :----------------- | | Total Profit | -36.3042 Million RMB | | Net Profit Attributable to Parent Company Shareholders | -36.7430 Million RMB | | Net Profit Attributable to Parent Company Shareholders After Deducting Non-Recurring Gains and Losses | -50.1754 Million RMB | | Earnings Per Share | -0.0217 RMB | [Primary Reasons for Current Period's Estimated Loss](index=2&type=section&id=三%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E4%BA%8F%E7%9A%84%E4%B8%BB%E8%A6%81%E5%8E%9F%E5%9B%A0) The estimated loss primarily stems from core business challenges, including high fixed costs in hospital operations during market cultivation and high production costs in coal mining due to limited output and declining market prices, partially offset by positive non-operating gains [Impact of Core Business Operations](index=2&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%BD%B1%E5%93%8D) Core business losses are driven by hospital operations facing high fixed costs despite revenue growth, and coal mining experiencing high production costs due to limited output and declining market prices - Hospital business remains in its market and reputation cultivation phase, with increasing operating revenue insufficient to cover high fixed costs, including labor, depreciation, amortization, and financial expenses, leading to continuous losses[6](index=6&type=chunk) - Coal mining business, despite increased production and sales, faces high production costs due to most mining faces being in the excavation layout stage, resulting in low overall raw coal output; declining coal market prices in 2025 further negatively impacted the business, leading to losses[6](index=6&type=chunk) [Impact of Non-Operating Gains and Losses](index=2&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89%E9%9D%9E%E7%BB%8F%E8%90%A5%E6%80%A7%E6%8D%9F%E7%9B%8A%E7%9A%84%E5%BD%B1%E5%93%8D) Non-operating gains and losses positively impacted net profit by approximately **RMB 1.1 million** in H1 2025, primarily from government subsidies recognized in current period profit or loss - Non-operating gains and losses had a positive impact of approximately **RMB 1.1 million** on net profit in the first half of 2025, primarily from government subsidies recognized in current period profit or loss[6](index=6&type=chunk) [Risk Warning](index=2&type=section&id=四%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company emphasizes that this performance forecast is a preliminary, unaudited financial department calculation, with no significant uncertainties identified that would impact its accuracy - The company states that this performance forecast is a preliminary calculation by the finance department and has not been audited by a certified public accountant[7](index=7&type=chunk) [Other Explanatory Matters](index=2&type=section&id=五%E3%80%81%E5%85%B6%E4%BB%96%E8%AF%B4%E6%98%8E%E4%BA%8B%E9%A1%B9) Investors are reminded that the disclosed data is preliminary, and final accurate financial data will be based on the officially released 2025 semi-annual report, with investment risks noted - The final accurate financial data will be based on the company's officially disclosed 2025 semi-annual report; investors are advised to be aware of investment risks[8](index=8&type=chunk)

Summary of Key Points Core Viewpoint The company has approved guarantees for its wholly-owned subsidiaries, Guizhou Daqin Tumor Hospital Co., Ltd. and Guizhou Chitianhua Tongzi Chemical Co., Ltd., to support their financing needs, with a total guarantee limit set for the year 2025. Group 1: Guarantee Overview - The company has approved a total guarantee amount of up to 1.8 billion yuan for its subsidiaries in 2025, including a maximum of 600 million yuan for third-party guarantees [1][2] - As of June 30, 2025, the total external guarantees provided by the company and its subsidiaries amount to 1.1702844 billion yuan, which is 45.99% of the company's latest audited net assets [1][15] - There are no overdue guarantees as of the announcement date [1][15] Group 2: Details of the Guaranteed Subsidiaries - Guizhou Daqin Tumor Hospital Co., Ltd. has total assets of 1.16916789 billion yuan and liabilities of 807.8614 million yuan as of March 31, 2025, with a net loss of 29.8208 million yuan in Q1 2025 [4][3] - Guizhou Chitianhua Tongzi Chemical Co., Ltd. has total assets of 2.7281658 billion yuan and liabilities of 1.1726276 billion yuan as of March 31, 2025, with a net profit of 1.37773 million yuan in Q1 2025 [6][5] Group 3: Guarantee Agreements - The company has entered into a guarantee agreement with Guizhou Bank for a loan of 30 million yuan to Guizhou Daqin Tumor Hospital, with a guarantee period of three years from the loan's maturity [7][6] - For Guizhou Chitianhua Tongzi Chemical, the company has provided guarantees for multiple loans, including a maximum of 145 million yuan for various financing needs, with similar guarantee terms [10][9] - The guarantees cover all principal, interest, penalties, and related costs incurred in the event of default [11][10]

证券代码：600227 证券简称：赤天化 编号：2025-048 贵州赤天化股份有限公司 关于提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●被担保人名称及是否为上市公司关联人：被担保人贵州大秦肿 瘤医院有限公司（以下简称"大秦医院"）和贵州赤天化桐梓化工有 限公司（以下简称"桐梓化工"）系公司的全资子公司。 ●本次担保金额及已实际为其提供的担保余额：①2025年6月， 公司对大秦医院增加担保金额为385万元，截止至2025年6月30日，公 司累计为大秦医院提供担保余额为61,148.44万元；②2025年6月，公 司对桐梓化工增加担保金额为9,223万元，截止至2025年6月30日，公 司累计为桐梓化工提供担保余额为55,880万元；2025年6月，公司提 供担保的子公司归还借款金额9,476.5万元，截止至2025年6月30日， 公司及公司控股子公司对外担保总额为117,028.44万元，对外担保均 为公司为报表合并范围内的子公司提供的担保。 ●本次担保是否有反担保：否 ●对外担保逾期 ...

Group 1 - The company has announced the cancellation of a fundraising special account following the completion of asset replacement transactions and the adjustment of investment projects [2][3][5] - The total amount raised through a non-public offering was approximately RMB 1.97 billion, with a net amount of approximately RMB 1.94 billion after deducting related fees [2] - The company has established a management system for the use of raised funds to enhance efficiency and protect investor rights, in compliance with relevant regulations [2][3] Group 2 - As of the announcement date, the balance of the fundraising special account was fully transferred to the company's basic account, and the account has been officially canceled [5] - The company has terminated the relevant fundraising special account storage supervision agreements with the banks and underwriters involved [5][6] - The company plans to permanently supplement the remaining raised funds into working capital for daily operations and business development [5]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会《关于核准贵州赤天化股份有限公司 向贵州渔阳贸易有限公司发行股份购买资产并募集配套资金的批复》 （证监许可[2016]2005 号）核准，贵州赤天化股份有限公司（以下 简称"公司"）以非公开发行方式发行人民币普通股（A股）327,787,021 股，募集资金总额为人民币 1,969,999,996.21 元，扣除发行费等相 关费用后，实际募集资金净额为 1,943,799,996.25 元。上述资金于 2016 年 10 月 14 日到账，经亚太（集团）会计师事务所（特殊普通 合伙）予以验证，并出具亚会 A 验字（2016）0212 号《验资报告》， 公司对募集资金采取了专户存储制度。 二、募集资金的使用与管理情况 为规范公司募集资金的管理和使用，提高募集资金使用效率与效 益，保护投资者权益，根据《上市公司监管指引第 2 号——上市公司 募集资金管理和使用的监管要求》、《上海证券交易所上市公司自律监 管指引第 1 号——规范运作》、《 ...

Group 1 - The legal opinion letter confirms that the convening and holding procedures of the second extraordinary general meeting of Guizhou Chitianhua Co., Ltd. comply with relevant laws, regulations, and the company's articles of association [3][5][9] - The meeting was convened by the company's board of directors and publicly announced on June 10, 2025, detailing the time, location, voting methods, and other relevant information [4][5] - A total of 739 shareholders (or their proxies) attended the meeting, representing 669,057,606 shares, which accounts for 39.8001% of the company's voting shares [5][6] Group 2 - The meeting adopted the proposal to adjust the investment scale of the fundraising project, with 657,467,140 shares voting in favor, representing 98.2676% of the valid votes [7][8] - The voting results for minority shareholders showed that 24,140,300 shares voted in favor, accounting for 67.5616% of the valid votes from minority shareholders [7] - The legal opinion concludes that the voting procedures and results are valid and comply with legal requirements [8][9]

证券代码：600227 证券简称：赤天化 公告编号：2025-046 贵州赤天化股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 739 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 669,057,606 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 39.8001 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 会议由公司董事会召集，董事长丁林洪主持，采取现场投票及网络投票相结 合的方式召开并表决。会议的召集和召开符合《公司法》、《上市公司股东会规则》 等相关法律法规和《公司章程》的规定。 (一) 股东大会召开的时间：2025 年 6 月 25 日 (二) 股东大会召开的地点：贵阳市观山湖区阳关大道 28 号赤天化大厦 22 楼 会议室 (三) ...